Electrode News and Research

RSS

Neurotech’s ADNS-300 system obtains European CE Mark approval

Neurotech s.a., a Belgium based developer and manufacturer of neurostimulation devices, announces that it has obtained the European CE Mark for its ADNS-300 system dedicated to the treatment of refractory epilepsy.

7 Jun 2012

Study describes how seizures in people with AS could be linked to brain cell activity imbalance

New research by scientists at the University of North Carolina School of Medicine may have pinpointed an underlying cause of the seizures that affect 90 percent of people with Angelman syndrome (AS), a neurodevelopmental disorder.

7 Jun 2012

Artificial noses could allow quick disease screening and ultimately transform diagnostics

Artificial noses have, until now, been used to detect diseases such as urinary tract infection, Helicobacter pylori, tuberculosis, ear, nose and throat conditions and even lung cancer. They have also been clinically tested for use in continuous monitoring of different disease stages.

7 Jun 2012

Brains of anxious girls work much harder than those of boys

In a discovery that could help in the identification and treatment of anxiety disorders, Michigan State University scientists say the brains of anxious girls work much harder than those of boys.

6 Jun 2012

Non-invasive stimulation of cerebellum helps individuals learn new walking patterns

In a step towards improving rehabilitation for patients with walking impairments, researchers from the Kennedy Krieger Institute found that non-invasive stimulation of the cerebellum, an area of the brain known to be essential in adaptive learning, helped healthy individuals learn a new walking pattern more rapidly.

2 Jun 2012

Electronic nose and optoacoustics improve diagnosis of prostate cancer

Chances of survival of prostate cancer depend strongly on the stage at which the disease is diagnosed. Now scientists have developed new methods relying on an electronic nose and optoacoustics to improve the diagnosis techniques and avoid fatal treatment delays

2 Jun 2012

Biochemiresistor can quickly detect small traces of contaminants in liquids

A whole new class of biosensor that can detect exceptionally small traces of contaminants in liquids in just 40 minutes has been developed by a UNSW-led team of researchers.

1 Jun 2012

Interim data from UCLA and NeuroSigma’s eTNS Phase I trial on PTSD, MDD

Today, at the 52nd annual New Clinical Drug Evaluation Unit (NCDEU) Conference in Arizona, Ian Cook, M.D., Professor of Psychiatry at the University of California, Los Angeles (UCLA) and a Senior Medical Advisor to NeuroSigma, Inc., presented the results from the first 6-subject cohort of a 10-subject Phase I open-label clinical trial studying the effects of external trigeminal nerve stimulation (eTNS) on Post-Traumatic Stress Disorder (PTSD) and depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy.

31 May 2012

Nevro to initiate Senza HF-SCS System study for chronic pain

Nevro Corp., a medical device company focused on achieving improved pain relief for patients suffering from debilitating chronic pain, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for initiation of its SENZA-RCT study, a U.S. prospective, randomized, controlled pivotal clinical trial evaluating the safety and efficacy of Nevro's high-frequency spinal cord stimulation system for the treatment of chronic pain.

24 May 2012

Science journal’s NEWSFOCUS section describes recent advances in sequencing technology

Rapid DNA sequencing may soon become a routine part of each individual's medical record, providing enormous information previously sequestered in the human genome's 3 billion nucleotide bases. This week's NEWSFOCUS section of the journal Science describes recent advances in sequencing technology.

From Oxford Nanopore Technologies 23 May 2012

Covidien launches new HALO ablation catheter to treat Barrett's esophagus

Covidien, a leading global provider of healthcare products, today announced the launch of the HALO90 ULTRA Ablation Catheter, the latest addition to the HALO family of catheters for the endoscopic treatment of Barrett's esophagus.

18 May 2012

Paper-based diabetes device can be adapted for other applications

With epidemics of Type 2 diabetes looming in rural India, China and other areas of the world where poverty limits the availability of health care, scientists are reporting development of an inexpensive and easy-to-use urine test ideally suited for such areas. The report describing the paper-based device, which also could be adapted for the diagnosis and monitoring of other conditions and the environment, appears in ACS' journal Analytical Chemistry.

17 May 2012

Ultrasensitive biosensor may open up new opportunities for early detection of cancer

Researchers have created an ultrasensitive biosensor that could open up new opportunities for early detection of cancer and "personalized medicine" tailored to the specific biochemistry of individual patients.

16 May 2012

Age-adjusted melanoma on the rise

As the U.S. observes Skin Cancer Awareness Month in May, a report published in the April issue of Mayo Clinic Proceedings has some sobering news for young adults: The incidence of melanoma increased eightfold among young women and fourfold among young men from 1970 through 2009.

16 May 2012

Encision fourth quarter revenue increases to $3.370 million

Encision Inc., a medical device company owning patented surgical technology that is emerging as a standard of care in minimally-invasive surgery, today announced financial results for its fiscal 2012 fourth quarter and fiscal year ended March 31, 2012.

14 May 2012

Study demonstrates accuracy of AliveCor’s iPhone-based ECG

AliveCor, the developer of a breakthrough mobile electrocardiogram (ECG) recorder, today announced results from a study that demonstrated the accuracy of the company's iPhone-based device, by comparing its Lead I to Lead I from a conventional 12-lead ECG. The study found that the iPhone-based event recorder is an accurate clinical tool for ECG assessment and could prove to be a new tool for allowing immediate recording and analysis of an ECG rhythm.

From AliveCor, Inc. 14 May 2012

Novel heart monitoring device helps ER patients avoid unnecessary follow-up care

A study conducted at Scripps Health has found that a novel new heart monitoring device helped emergency room patients avoid unnecessary follow-up care. Scripps Health electrophysiologist Steven Higgins, MD, presented findings of the study titled, "Prevalence of Arrhythmias in Emergency Department Patients Discharged Using a Novel Ambulatory Cardiac Monitor", today at the Heart Rhythm Society's 33rd Annual Scientific Sessions in Boston.

14 May 2012

New system may help restore vision in eye diseases

Using tiny solar-panel-like cells surgically placed underneath the retina, scientists at the Stanford University School of Medicine have devised a system that may someday restore sight to people who have lost vision because of certain types of degenerative eye diseases.

14 May 2012

Sorin launches full portfolio of pacing, defibrillation and left ventricular leads

Sorin Group, a global medical device company and a leader in the treatment of cardiovascular diseases, announced today at Heart Rhythm 2012, the Heart Rhythm Society's 33rd Annual Scientific Sessions, FDA approval and commercial launch for a full portfolio of pacing, defibrillation and left ventricular leads.

11 May 2012

Results reported for clinical trial for the treatment of depression using external trigeminal nerve stimulation

Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.

9 May 2012

Electrode News and Research

Neurotech’s ADNS-300 system obtains European CE Mark approval

Study describes how seizures in people with AS could be linked to brain cell activity imbalance

Artificial noses could allow quick disease screening and ultimately transform diagnostics

Brains of anxious girls work much harder than those of boys

Non-invasive stimulation of cerebellum helps individuals learn new walking patterns

Electronic nose and optoacoustics improve diagnosis of prostate cancer

Biochemiresistor can quickly detect small traces of contaminants in liquids

Interim data from UCLA and NeuroSigma’s eTNS Phase I trial on PTSD, MDD

Nevro to initiate Senza HF-SCS System study for chronic pain

Science journal’s NEWSFOCUS section describes recent advances in sequencing technology

Covidien launches new HALO ablation catheter to treat Barrett's esophagus

Paper-based diabetes device can be adapted for other applications

Ultrasensitive biosensor may open up new opportunities for early detection of cancer

Age-adjusted melanoma on the rise

Encision fourth quarter revenue increases to $3.370 million

Study demonstrates accuracy of AliveCor’s iPhone-based ECG

Novel heart monitoring device helps ER patients avoid unnecessary follow-up care

New system may help restore vision in eye diseases

Sorin launches full portfolio of pacing, defibrillation and left ventricular leads

Results reported for clinical trial for the treatment of depression using external trigeminal nerve stimulation

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News